← All indications
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
Drugs by status
Phase 2 trials (4)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (21)
- Teva
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Cornell University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Guangzhou Medical University
- Johns Hopkins University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- University of South Florida
- Mayo Clinic
- Peking University
- Southern Medical University
- Sun Yat-Sen University
- Technion University
- University of Texas at Houston
- State University of New York, Buffalo
- State of Texas
- Yeshiva University
Organization Involved with Phase 1 Indications (12)